EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 581 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BPIQ-I
CAS:BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.Fórmula:C16H12BrN5Forma y color:SolidPeso molecular:354.2BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Fórmula:C27H28ClFN8O3Pureza:99.98%Forma y color:SolidPeso molecular:567.01EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Fórmula:C31H34N6O3Forma y color:SolidPeso molecular:538.64MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Fórmula:C46H54ClFN8O8Forma y color:SolidPeso molecular:901.42EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97EGFR-IN-1
CAS:EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.
Fórmula:C28H30N6O4Pureza:98%Forma y color:SolidPeso molecular:514.58EGFR-IN-85
CAS:EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFRFórmula:C26H30N8O2Pureza:98%Forma y color:SolidPeso molecular:486.57EGFR-IN-61
CAS:EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).Fórmula:C33H37ClN8O3Pureza:98%Forma y color:SolidPeso molecular:629.15EGFR-IN-33
CAS:EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97BGB-102
CAS:BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.Fórmula:C22H25BrN4O2Pureza:99.02%Forma y color:SolidPeso molecular:457.36JGK-068S
CAS:Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35DZD1516
CAS:DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFórmula:C28H27F2N7O3Pureza:98%Forma y color:SolidPeso molecular:547.562′-Thioadenosine
CAS:2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM againstFórmula:C10H13N5O3SPureza:98%Forma y color:SolidPeso molecular:283.31EGFR/ErbB-2 inhibitor-1
CAS:EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.Fórmula:C23H15ClFN3OS2Pureza:98.93%Forma y color:SolidPeso molecular:467.97EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Fórmula:C28H33N7O2Pureza:98.64%Forma y color:SolidPeso molecular:499.61EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Fórmula:C28H31ClN6O4Pureza:99.16%Forma y color:SolidPeso molecular:551.04Ref: TM-T11157L
1mg62,00€5mg142,00€10mg205,00€25mg319,00€50mg429,00€100mg587,00€200mg795,00€1mL*10mM (DMSO)190,00€Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Fórmula:C24H25ClN4O5Pureza:99.81%Forma y color:SolidPeso molecular:484.93EGFR-IN-8
CAS:EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC
Fórmula:C32H23ClF3N7O4Pureza:99.51%Forma y color:SolidPeso molecular:662.02EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Fórmula:C27H31ClN7O3PForma y color:SolidPeso molecular:568.01Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Fórmula:C24H24Br2ClN9O3Pureza:99.52%Forma y color:SolidPeso molecular:681.77Ref: TM-T13088
1mg133,00€5mg268,00€10mg409,00€25mg670,00€50mg888,00€100mg1.243,00€1mL*10mM (DMSO)414,00€EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Fórmula:C30H35FN6O3Forma y color:SolidPeso molecular:546.64JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Fórmula:C31H29FN4O3SForma y color:SolidPeso molecular:556.65HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Fórmula:C19H14BrF3N2OForma y color:SolidPeso molecular:423.23EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Fórmula:C33H28N6O3SForma y color:SolidPeso molecular:588.68JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Fórmula:C26H27ClN6O2Forma y color:SolidPeso molecular:490.98Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Fórmula:C10H8N2OForma y color:SolidPeso molecular:172.183EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Fórmula:C12H14N4OS2Forma y color:SolidPeso molecular:294.4EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Fórmula:C16H16N4O2SForma y color:SolidPeso molecular:328.39EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Forma y color:SolidEGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Fórmula:C27H25N3O6SForma y color:SolidPeso molecular:519.57D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Fórmula:C25H26Cl2FN7O3Forma y color:SolidPeso molecular:562.42HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Fórmula:C28H26F3N7O3Forma y color:SolidPeso molecular:565.55LSD1/EGFR-IN-1
CAS:LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.
Fórmula:C21H20ClN3O4Forma y color:SolidPeso molecular:413.854EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Fórmula:C27H31N7O3Forma y color:SolidPeso molecular:501.58Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Fórmula:C25H26BrClN6OSForma y color:SolidPeso molecular:573.94HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Fórmula:C26H25F2N9O3Forma y color:SolidPeso molecular:549.53NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Fórmula:C20H16O7Forma y color:SolidPeso molecular:368.34BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Fórmula:C18H15N3O2Forma y color:SolidPeso molecular:305.331Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Fórmula:C32H31ClN6O4Forma y color:SolidPeso molecular:599.08EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Fórmula:C26H28ClN3O4Forma y color:SolidPeso molecular:481.97HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Fórmula:C26H32N8O3Forma y color:SolidPeso molecular:504.58EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96Neptinib
CAS:Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.90EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Fórmula:C14H11BrN4O2SForma y color:SolidPeso molecular:379.23EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96EGFR Ligand-Linker Conjugates 1
CAS:EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Fórmula:C37H47N9O3Forma y color:SolidPeso molecular:665.83EGFR-IN-159
CAS:EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.Fórmula:C21H23N3O5Forma y color:SolidPeso molecular:397.424BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Fórmula:C29H33ClN8O4Forma y color:SolidPeso molecular:593.08SORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Fórmula:C19H31NO6SForma y color:SolidPeso molecular:401.52
